AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26111544 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone (HYD) 20 to 120 mg taken once daily, average daily dose 57 mg
Number of subjects: 588
Study 26111544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study 24042367 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline, 1 mg twice daily for 12 weeks
Number of subjects: 525
Study 24042367 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 525
Study 24042367 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 525
Study 24042367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 525
Study 20929973 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic implicit sequence-learning task performed by young adults
Number of subjects: 0
Study 20929973 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic implicit sequence-learning task performed by elderly adults
Number of subjects: 0
Study 20929973 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic implicit sequence-learning task for both age groups
Number of subjects: 0
Study 19636019 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-modality therapy (transurethral resection bladder tumor [TURBT], radiation therapy, chemotherapy)
Number of subjects: 285
Study 16757181 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.5 mg/kg)
Number of subjects: 15
Study 16757181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15275781 — intervention group
Group type: COMPARATOR
Intervention: Electronic questionnaires (E)
Number of subjects: 189
Study 15275781 — intervention group
Group type: COMPARATOR
Intervention: Paper questionnaires (P)
Number of subjects: 189
Study 15275781 — intervention group
Group type: COMPARATOR
Intervention: Comparison of mean difference scores between E and P
Number of subjects: 189
Study 15275781 — intervention group
Group type: COMPARATOR
Intervention: Anxiety and experience scores
Number of subjects: 189
Study 11736883 — intervention group
Group type: EXPERIMENTAL
Intervention: Finrozole 3 mg tablets
Number of subjects: 23
Study 11736883 — intervention group
Group type: EXPERIMENTAL
Intervention: Finrozole 9 mg tablets
Number of subjects: 23
Study 11736883 — intervention group
Group type: EXPERIMENTAL
Intervention: Finrozole 30 mg tablets
Number of subjects: 23
Study 11736883 — intervention group
Group type: EXPERIMENTAL
Intervention: Finrozole solution (dosage not specified)
Number of subjects: 23
Study 11736883 — intervention group
Group type: EXPERIMENTAL
Intervention: Finrozole tablets (general)
Number of subjects: 23
Study 11736883 — intervention group
Group type: COMPARATOR
Intervention: Finrozole 3 mg tablets vs 9 mg tablets
Number of subjects: 23
Study 9348763 — intervention group
Group type: EXPERIMENTAL
Intervention: Global interventions addressing risk factors for loss of mobility and functional decline
Number of subjects: 0
Study 9348763 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment and management
Number of subjects: 0
Study 8501458 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced education condition (slide-lecture show about kidney diseases and treatment)
Number of subjects: 204
Study 8501458 — intervention group
Group type: COMPARATOR
Intervention: Standard education condition (routine educational procedures at the hospital)
Number of subjects: 204
Study 3442182 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 10
Study 3442182 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 10
Study 30045307 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow yeast rice (1 pouch containing monacolin K) twice daily for 8 weeks
Number of subjects: 68
Study 30045307 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 8 weeks)
Number of subjects: 68
Study 27330183 — intervention group
Group type: EXPERIMENTAL
Intervention: Being observed by an ingroup member
Number of subjects: 0
Study 27330183 — intervention group
Group type: COMPARATOR
Intervention: Being observed by an outgroup member
Number of subjects: 0
Study 27330183 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with greater intergroup bias
Number of subjects: 0
Study 26162648 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated physical activity intervention (n = 58)
Number of subjects: 116
Study 26162648 — intervention group
Group type: COMPARATOR
Intervention: Online health education course (n = 58)
Number of subjects: 116
Study 23973688 — intervention group
Group type: COMPARATOR
Intervention: simvastatin plus placebo
Number of subjects: 0
Study 23973688 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin plus extended-release niacin (ERN, 1,500 to 2,000 mg/day)
Number of subjects: 0
Study 21079438 — intervention group
Group type: EXPERIMENTAL
Intervention: New off-the-shelf insert
Number of subjects: 15
Study 21079438 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion-control shoe
Number of subjects: 15
Study 21079438 — intervention group
Group type: COMPARATOR
Intervention: Existing off-the-shelf insert
Number of subjects: 15
Study 17308269 — intervention group
Group type: EXPERIMENTAL
Intervention: AC (doxorubicin 54 mg/m2 and cyclophosphamide 1.2 g/m2 IV every 3 weeks for six cycles)
Number of subjects: 3176
Study 17308269 — intervention group
Group type: COMPARATOR
Intervention: A -> C (doxorubicin 40.5 mg/m2 IV days 1 and 2 every 3 weeks for four cycles followed by cyclophosphamide 2.4 gm/m2 IV every 2 weeks for three cycles)
Number of subjects: 3176
Study 17308269 — intervention group
Group type: EXPERIMENTAL
Intervention: A -> C
Number of subjects: 3176
Study 17308269 — intervention group
Group type: COMPARATOR
Intervention: AC
Number of subjects: 3176
Study 14770192 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg daily
Number of subjects: 236
Study 14770192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 11700811 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter-only intervention (5 hospitals)
Number of subjects: 1117
Study 11700811 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter+visit intervention (5 hospitals)
Number of subjects: 1117
Study 11700811 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1117
Study 9741602 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonophoresis (PH) with 0.05% fluocinonide gel
Number of subjects: 49
Study 9741602 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (US) alone with an identical gel absent the steroid
Number of subjects: 49
Study 7528288 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterosgel application
Number of subjects: 0
Study 7528288 — intervention group
Group type: COMPARATOR
Intervention: Hepar
Number of subjects: 0
Study 3182440 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiramycin
Number of subjects: 96
Study 3182440 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 96
Study 3182440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 30763939 — intervention group
Group type: COMPARATOR
Intervention: Raspberry supplementation (acute phase)
Number of subjects: 0
Study 30763939 — intervention group
Group type: COMPARATOR
Intervention: Four-week daily raspberry supplementation
Number of subjects: 0
Study 30763939 — intervention group
Group type: COMPARATOR
Intervention: Control phase
Number of subjects: 0
Study 30573476 — intervention group
Group type: EXPERIMENTAL
Intervention: Management based on office blood pressure measurement (OBPM)
Number of subjects: 1240
Study 30573476 — intervention group
Group type: EXPERIMENTAL
Intervention: Management based on ambulatory blood pressure measurement (ABPM)
Number of subjects: 1240
Study 30573476 — intervention group
Group type: EXPERIMENTAL
Intervention: Management based on ABPM
Number of subjects: 1240
Study 30573476 — intervention group
Group type: EXPERIMENTAL
Intervention: Management based on OBPM
Number of subjects: 1240
Study 27131926 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered Stents (CS)
Number of subjects: 125
Study 27131926 — intervention group
Group type: COMPARATOR
Intervention: Bare-Metal Stents (BMS)
Number of subjects: 125
Study 25159818 — intervention group
Group type: EXPERIMENTAL
Intervention: HDACi 109 (RG2833) at doses ranging from 30mg/day to 240mg/day
Number of subjects: 0
Study 25159818 — intervention group
Group type: EXPERIMENTAL
Intervention: HDACi 109 (RG2833)
Number of subjects: 0
Study 22023516 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy followed by autologous stem cell transplantation
Number of subjects: 207
Study 22023516 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex karyotype, translocation t(4;14), gain of 1q21
Number of subjects: 207
Study 22023516 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex karyotype and translocation t(4;14)
Number of subjects: 207
Study 22023516 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal karyotype or karyotype with ≤ 2 chromosomal changes
Number of subjects: 207
Study 22023516 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex karyotype, translocation t(4;14), β(2)-microglobulin level > 2.5 mg/L
Number of subjects: 207
Study 20952767 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFA)
Number of subjects: 608
Study 20952767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608
Study 20952767 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 608
Study 20952767 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for rosuvastatin)
Number of subjects: 608
Study 17895943 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion therapy
Number of subjects: 0
Study 16762371 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (up to 6 mg)
Number of subjects: 36
Study 16762371 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (up to 15 mg)
Number of subjects: 36
Study 12811263 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP‐2 with CORNERSTONE‐SR Allograft Ring and ATLANTIS anterior cervical plate
Number of subjects: 33
Study 12811263 — intervention group
Group type: COMPARATOR
Intervention: Cancellous iliac crest autograft with CORNERSTONE‐SR Allograft Ring and ATLANTIS anterior cervical plate
Number of subjects: 33
Study 10227322 — intervention group
Group type: EXPERIMENTAL
Intervention: Outer-membrane protein (OMP) meningococcal vaccine
Number of subjects: 543
Study 8921053 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified follicle stimulating hormone (FSH, Metrodin High Purity) administered either i.m. (MHPim) or s.c. (MHPsc)
Number of subjects: 60
Study 8921053 — intervention group
Group type: COMPARATOR
Intervention: Human menopausal gonadotrophins (HMGim, Pergonal)
Number of subjects: 60
Study 8921053 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean circulating concentrations of LH in the follicular phase
Number of subjects: 60
Study 1862890 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 40
Study 1862890 — intervention group
Group type: COMPARATOR
Intervention: Diamorphine
Number of subjects: 40
Study 6638856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephradine prophylaxis (1 gram at induction of anaesthesia, followed by three postoperative doses of 1 gram at 6 hourly intervals)
Number of subjects: 35
Study 6638856 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cephradine prophylaxis)
Number of subjects: 35
Study 30705033 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive dose escalation (group B)
Number of subjects: 245
Study 30705033 — intervention group
Group type: COMPARATOR
Intervention: Standard dose escalation (group A)
Number of subjects: 245
Study 29268719 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured dietary intervention delivered by primary care nurses with visits at baseline, 2-3 weeks, 3 months, and 6 months.
Number of subjects: 157
Study 29268719 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by control practices.
Number of subjects: 157
Study 26031344 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face intensive training programme
Number of subjects: 390
Study 26031344 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face intensive training programme and an educational video
Number of subjects: 390
Study 26031344 — intervention group
Group type: COMPARATOR
Intervention: Continuous nursing education
Number of subjects: 390
Study 26031344 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 390
Study 26265275 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5mg
Number of subjects: 3635
Study 26265275 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25mg
Number of subjects: 3635
Study 21359834 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 462
Study 21359834 — intervention group
Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 462
Study 21359834 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone and Glipizide
Number of subjects: 462
Study 19240522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular sodium hyaluronate injections at weekly intervals for 3 weeks
Number of subjects: 33
Study 17637266 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 50 microg/h for 72 h (Group A)
Number of subjects: 26
Study 17637266 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 25 microg/h for 72 h (Group B)
Number of subjects: 26
Study 17637266 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Group A and Group B
Number of subjects: 26
Study 17637266 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 26
Study 17637266 — intervention group
Group type: EXPERIMENTAL
Intervention: PFV(max) and PFV(mean)
Number of subjects: 26
Study 17637266 — intervention group
Group type: EXPERIMENTAL
Intervention: HAV(max) and HAV(min)
Number of subjects: 26
Study 14699268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention and exercises
Number of subjects: 124
Study 14699268 — intervention group
Group type: COMPARATOR
Intervention: Lumbar fusion
Number of subjects: 124
Study 12580357 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (X)
Number of subjects: 98
Study 12580357 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol (S)
Number of subjects: 98
Study 12580357 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 mixture of xylitol and erythritol (XE)
Number of subjects: 98
Study 12580357 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 mixture of sorbitol and erythritol (SE)
Number of subjects: 98
Study 10579376 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 lux bright white light
Number of subjects: 34
Study 10579376 — intervention group
Group type: COMPARATOR
Intervention: 50 lux dim red light (placebo control)
Number of subjects: 34
Study 10579376 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 7564973 — intervention group
Group type: COMPARATOR
Intervention: Water placebo (WP)
Number of subjects: 10
Study 7564973 — intervention group
Group type: COMPARATOR
Intervention: Water placebo + 280 mg nicotinic acid.l‐1 (WP + NA)
Number of subjects: 10
Study 7564973 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate‐electrolyte beverage (CE)
Number of subjects: 10
Study 7564973 — intervention group
Group type: EXPERIMENTAL
Intervention: CE + NA
Number of subjects: 10
Study 7564973 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid ingestion (WP + NA and CE + NA)
Number of subjects: 10
Study 2169782 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms/kg)
Number of subjects: 28
Study 2169782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 6927816 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg Ro 13-5057
Number of subjects: 10
Study 6927816 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg Ro 13-5057
Number of subjects: 10
Study 6927816 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg Ro 13-5057
Number of subjects: 10
Study 6927816 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg piracetam
Number of subjects: 10
Study 6927816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31520930 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose (LD) CBCT
Number of subjects: 16
Study 31520930 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose (FD) CBCT
Number of subjects: 16
Study 31520930 — intervention group
Group type: COMPARATOR
Intervention: Multi-slice CT (MSCT)
Number of subjects: 16
Study 31520930 — intervention group
Group type: COMPARATOR
Intervention: MSCT
Number of subjects: 16
Study 31520930 — intervention group
Group type: EXPERIMENTAL
Intervention: FD CBCT
Number of subjects: 16
Study 31520930 — intervention group
Group type: EXPERIMENTAL
Intervention: LD CBCT
Number of subjects: 16
Study 27734549 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (2.5 mcg·kg‐1)
Number of subjects: 59
Study 27734549 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam (0.5 mg·kg‐1)
Number of subjects: 59
Study 26026776 — intervention group
Group type: EXPERIMENTAL
Intervention: Student-directed group (SDG)
Number of subjects: 177
Study 26026776 — intervention group
Group type: COMPARATOR
Intervention: Instructor-directed group (IDG)
Number of subjects: 177
Study 26026776 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 177
Study 24136973 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence BOOST
Number of subjects: 22
Study 24136973 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOOM2
Number of subjects: 22
Study 21087463 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebeverine (anti-spasmodic)
Number of subjects: 135
Study 21087463 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcellulose (bulking-agent)
Number of subjects: 135
Study 21087463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 21087463 — intervention group
Group type: EXPERIMENTAL
Intervention: Regul8 with nurse telephone session and email support
Number of subjects: 135
Study 21087463 — intervention group
Group type: EXPERIMENTAL
Intervention: Regul8 with minimal email support
Number of subjects: 135
Study 21087463 — intervention group
Group type: COMPARATOR
Intervention: No website
Number of subjects: 135
Study 18765312 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose involved-field radiation therapy (LD-IFRT) at 4 Gy in 2 fractions
Number of subjects: 36
Study 16706811 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic stimulation of the S2-S3 dermatomes
Number of subjects: 14
Study 16706811 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 14
Study 14600529 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental malaria
Number of subjects: 746
Study 14600529 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV viral load
Number of subjects: 746
Study 10973134 — intervention group
Group type: EXPERIMENTAL
Intervention: Perimenopausal period
Number of subjects: 25
Study 8818847 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 10 mg/kg once daily for 3 days
Number of subjects: 259
Study 8818847 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 40 mg/kg daily in divided doses every 8 h for 10 days
Number of subjects: 259
Study 1483372 — intervention group
Group type: EXPERIMENTAL
Intervention: No-stitch small incision cataract surgery
Number of subjects: 65
Study 1483372 — intervention group
Group type: COMPARATOR
Intervention: Conventional 3.5 mm scleral step incision
Number of subjects: 65
Study 2933998 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol 50 micrograms b.d.
Number of subjects: 0
Study 2933998 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol 100 micrograms b.d.
Number of subjects: 0
Study 2933998 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 5 mg t.i.d.
Number of subjects: 0
Study 2933998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31780015 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage for 30 min/day, five days a week for eight weeks
Number of subjects: 35
Study 31780015 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Number of subjects: 35
Study 31780015 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 35
Study 30119284 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral thyroxin (5 μg/kg) administered 12 hours before surgery and once daily during ICU stay
Number of subjects: 100
Study 30119284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27467027 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (30 sessions of low-frequency right-sided rTMS at the right DLPFC)
Number of subjects: 25
Study 27467027 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (sham coil)
Number of subjects: 25
Study 24357270 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 727
Study 22525511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided BC aspiration and corticosteroid injection (Group A)
Number of subjects: 60
Study 22525511 — intervention group
Group type: COMPARATOR
Intervention: Horizontal Therapy (Group B)
Number of subjects: 60
Study 22525511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided BC aspiration and corticosteroid injection plus Horizontal therapy (Group C)
Number of subjects: 60
Study 20860128 — intervention group
Group type: EXPERIMENTAL
Intervention: Fir bark splint fixation
Number of subjects: 80
Study 20860128 — intervention group
Group type: COMPARATOR
Intervention: Plaster fixation
Number of subjects: 80
Study 19088847 — intervention group
Group type: COMPARATOR
Intervention: Invalid trials (invalid spatial cues)
Number of subjects: 0
Study 19088847 — intervention group
Group type: EXPERIMENTAL
Intervention: Valid trials (valid spatial cues)
Number of subjects: 0
Study 17955948 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity at 30 W and 60 W for 4 min at 2134 m
Number of subjects: 6
Study 17955948 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity at 30 W and 60 W for 4 min at 2743 m
Number of subjects: 6
Study 17955948 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity at 30 W and 60 W for 4 min at sea level
Number of subjects: 6